Effects of antidepressant drugs and GR 205171, an neurokinin-1 (NK1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse

Neuroscience Letters

Volumn 345, Issue 2, 2003, Pages 73-76

  Zocchi, Alessandro ^a   Varnier, Giorgia ^a   Arban, Roberto ^a   Griffante, Cristiana ^a   Zanetti, Lara ^a   Bettelini, Letizia ^a   Marchi, Mario ^b   Gerrard, Philip A ^a   Corsi, Mauro ^a  

^a GSK   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Antidepressants; Brain monoamines; Forced swim test; Microdialysis; Mouse

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; MONOAMINE; NEUROKININ 1 RECEPTOR ANTAGONIST; VOFOPITANT;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; FRONTAL CORTEX; IMMOBILIZATION; MICRODIALYSIS; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SWIMMING;

EID: 0038718697     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00305-7     Document Type: Article

References (20)

1. 1 receptor antagonist. Br. J. Pharmacol. 116:1995;3149-3157.
2. Beresford I.J., Birch P.J., Hagan R.M., Ireland S.J. Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345. Br. J. Pharmacol. 104:1991;292-293.
3. Bourin M., Colombel M.C., Redrobe J.P., Nizard J., Hascoet M., Baker G.B. Evaluation of efficacies of different classes of antidepressant in the forced swimming test in mice at different ages. Pro. Neuro-Psychopharmacol. Biol. Psychiatry. 22:1998;343-351.
4. Conley R.K., Cumberbatch M.J., Mason G.S., Williamson D.J., Harrison T., Locker K., Swain C., Maubach K., O'Donnell R., Rigby M., Hewson L., Smith D., Rupniak N.M. Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity. J. Neurosci. 22:2002;7730-7736.
5. Cooper B.R., Wang C.M., Cox R.F., Norton R., Shea V., Ferris R.M. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology. 11:1994;133-141.
6. D'Aquila P.S., Collu M., Gessa G.L., Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur. J. Pharmacol. 405:2000;365-373.
7. Ferris R.M., Cooper B.R., Maxwell R.A. Studies of bupropion's mechanism of antidepressant activity. J. Clin. Psychiatry. 44:1983;74-78.
8. Gardner C.J., Armour D.R., Beattie D.T., Gale J.D., Hawcock A.B., Kilpatrick G.J., Twissel D.J., Ward P. GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regul. Pept. 65:1996;45-53.
9. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., Reines S.A., Liu G., Snavely D., Wyatt-Knowles E., Hale J.J., Mills S.G., MacCoss M., Swain C.J., Harrison T., Hill R.G., Hefti F., Scolnick E.M., Cascieri M.A., Chicchi G.G., Sadowski S., Williams A.R., Hewson L., Smith D., Rupniak N.M. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 281:1998;1640-1645.
10. Maubach K.A., Martin K., Chicchi G., Harrison T., Wheeldon A., Swain C.J., Cumberbatch M.J., Rupniak N.M., Seabrook G.R. Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus. Neuroscience. 109:2002;609-617.
11. Millan M.J., Lejeune F., De Nanteuil G., Gobert A. Selective blockade of neurokinin (NK)1 receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats. J. Neurochem. 76:2001;1949-1954.
12. Millan M.J., Lejeune F., Gobert A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J. Psychopharmacol. 14:2000;114-138.
13. 1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats. Behav. Brain Res. 115:2000;19-23.
14. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressant. Arch. Int. Pharmacodyn. 229:1977;327-336.
15. Reneric J.P., Lucki I. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychoparmacology. 136:1998;190-197.
16. 1 receptor) antagonists. Curr. Op. Invest. Drugs. 3:2002;257-261.
17. 1) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology. 39:2000;1413-1421.
18. 1) receptor in assays for antidepressant and anxiolytic drugs. Behav. Pharmacol. 12:2001;497-508.
19. 1) antagonists. Trends Pharmacol. Sci. 20:1999;485-490.
20. Wong D.T., Bymaster F.P., Engleman E.A. Prozac (fluoxetine, LILLY 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: 20 years since its first publication. Life Sci. 57:1995;411-441.